273 related articles for article (PubMed ID: 22183643)
1. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma.
Favier J; Igaz P; Burnichon N; Amar L; Libé R; Badoual C; Tissier F; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP
Endocr Pathol; 2012 Mar; 23(1):34-42. PubMed ID: 22183643
[TBL] [Abstract][Full Text] [Related]
2. The mTORC1 Complex Is Significantly Overactivated in SDHX-Mutated Paragangliomas.
Oudijk L; Papathomas T; de Krijger R; Korpershoek E; Gimenez-Roqueplo AP; Favier J; Canu L; Mannelli M; Rapa I; Currás-Freixes M; Robledo M; Smid M; Papotti M; Volante M
Neuroendocrinology; 2017; 105(4):384-393. PubMed ID: 28122379
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors.
Favier J; Plouin PF; Corvol P; Gasc JM
Am J Pathol; 2002 Oct; 161(4):1235-46. PubMed ID: 12368197
[TBL] [Abstract][Full Text] [Related]
5. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
6. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
7. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract][Full Text] [Related]
9. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
[TBL] [Abstract][Full Text] [Related]
10. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
[TBL] [Abstract][Full Text] [Related]
11. Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
Mete O; Pakbaz S; Lerario AM; Giordano TJ; Asa SL
Am J Surg Pathol; 2021 Sep; 45(9):1264-1273. PubMed ID: 33826547
[TBL] [Abstract][Full Text] [Related]
12. Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis.
Lussey-Lepoutre C; Buffet A; Morin A; Goncalves J; Favier J
Cell Tissue Res; 2018 May; 372(2):379-392. PubMed ID: 29427052
[TBL] [Abstract][Full Text] [Related]
13. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
[TBL] [Abstract][Full Text] [Related]
14. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma.
Burnichon N; Vescovo L; Amar L; Libé R; de Reynies A; Venisse A; Jouanno E; Laurendeau I; Parfait B; Bertherat J; Plouin PF; Jeunemaitre X; Favier J; Gimenez-Roqueplo AP
Hum Mol Genet; 2011 Oct; 20(20):3974-85. PubMed ID: 21784903
[TBL] [Abstract][Full Text] [Related]
15. The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas.
Andreasson A; Kiss NB; Caramuta S; Sulaiman L; Svahn F; Bäckdahl M; Höög A; Juhlin CC; Larsson C
Epigenetics; 2013 Dec; 8(12):1347-54. PubMed ID: 24149047
[TBL] [Abstract][Full Text] [Related]
16. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations.
Loriot C; Burnichon N; Gadessaud N; Vescovo L; Amar L; Libé R; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2012 Jun; 97(6):E954-62. PubMed ID: 22492777
[TBL] [Abstract][Full Text] [Related]
17. A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma.
Burnichon N; Lepoutre-Lussey C; Laffaire J; Gadessaud N; Molinié V; Hernigou A; Plouin PF; Jeunemaitre X; Favier J; Gimenez-Roqueplo AP
Eur J Endocrinol; 2011 Jan; 164(1):141-5. PubMed ID: 20923864
[TBL] [Abstract][Full Text] [Related]
18. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas.
Yao L; Schiavi F; Cascon A; Qin Y; Inglada-Pérez L; King EE; Toledo RA; Ercolino T; Rapizzi E; Ricketts CJ; Mori L; Giacchè M; Mendola A; Taschin E; Boaretto F; Loli P; Iacobone M; Rossi GP; Biondi B; Lima-Junior JV; Kater CE; Bex M; Vikkula M; Grossman AB; Gruber SB; Barontini M; Persu A; Castellano M; Toledo SP; Maher ER; Mannelli M; Opocher G; Robledo M; Dahia PL
JAMA; 2010 Dec; 304(23):2611-9. PubMed ID: 21156949
[TBL] [Abstract][Full Text] [Related]
19. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
[TBL] [Abstract][Full Text] [Related]
20. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.
Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL
Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
